{"id":18659,"date":"2024-12-19T13:36:29","date_gmt":"2024-12-19T14:36:29","guid":{"rendered":"http:\/\/medexperts.pro\/?p=18659"},"modified":"2024-12-19T15:24:50","modified_gmt":"2024-12-19T15:24:50","slug":"popular-arthritis-drug-for-dogs-may-have-severe-side-effects-f-d-a-says","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=18659","title":{"rendered":"Popular Arthritis Drug For Dogs May Have Severe Side Effects, F.D.A. Says"},"content":{"rendered":"
<\/div>\n

The agency recommended that the maker of Librela update its label to reflect the possibility of more serious adverse reactions.<\/p>\n

\n
\n
\n

A popular drug for dogs with arthritis may be associated with a variety of potentially severe neurological effects, including seizures and a loss of muscle control, according to a recent review<\/a> by the U.S. Food and Drug Administration, which approved the drug last year. In some cases, dogs have died or have been euthanized after developing these symptoms, the agency noted.<\/p>\n

The drug, called Librela, is an injection of monoclonal antibodies that is approved for arthritis-related pain in dogs. Its label lists mostly mild side effects, such as urinary tract and skin infections.<\/p>\n

But since the drug became widely available, some pet owners have reported that their dogs became seriously ill, lost the ability to walk or stand or even died shortly after receiving the drug.<\/p>\n

The F.D.A.\u2019s analysis, which is based on more than 3,600 adverse-event reports submitted to the agency and the drug manufacturer, does not prove that Librela caused these problems or estimate how frequently they might occur.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

But such reviews can help regulators identify potential side effects that smaller clinical trials may have missed. The F.D.A. has alerted<\/a> veterinarians to the adverse events that may be associated with Librela and recommended that the drug\u2019s label be updated to include them.<\/p>\n

Zoetis, the company that makes Librela, said that more than 21 million doses of the drug had been distributed globally and that side effects were rare. \u201cWe at Zoetis \u2014 and I personally \u2014 stand 100 percent behind Librela as safe and effective,\u201d said Dr. Richard Goldstein, the company\u2019s chief medical officer.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The agency recommended that the maker of Librela update its label to reflect the possibility of more serious adverse reactions.A popular drug for dogs with arthritis may be associated with a variety of potentially severe neurological effects, including seizures and a loss of muscle control, according to a recent review by the U.S. Food and Drug Administration, which approved the drug last year. In some cases, dogs have died or have been euthanized after developing these symptoms, the agency noted.The drug, called Librela, is an injection of monoclonal antibodies that is approved for arthritis-related pain in dogs. Its label lists mostly mild side effects, such as urinary tract and skin infections.But since the drug became widely available, some pet owners have reported that their dogs became seriously ill, lost the ability to walk or stand or even died shortly after receiving the drug.The F.D.A.\u2019s analysis, which is based on more than 3,600 adverse-event reports submitted to the agency and the drug manufacturer, does not prove that Librela caused these problems or estimate how frequently they might occur.But such reviews can help regulators identify potential side effects that smaller clinical trials may have missed. The F.D.A. has alerted veterinarians to the adverse events that may be associated with Librela and recommended that the drug\u2019s label be updated to include them.Zoetis, the company that makes Librela, said that more than 21 million doses of the drug had been distributed globally and that side effects were rare. \u201cWe at Zoetis \u2014 and I personally \u2014 stand 100 percent behind Librela as safe and effective,\u201d said Dr. Richard Goldstein, the company\u2019s chief medical officer.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":18661,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-18659","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18659"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18659\/revisions"}],"predecessor-version":[{"id":18662,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/18659\/revisions\/18662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/18661"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}